Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.
This activity is supported by educational grants from AstraZeneca, Celgene Corporation, and Helsinn Therapeutics (US), Inc.
Release Date: September 28, 2018
Expiration Date: September 28, 2019
Media: Internet - based
The 2nd Annual School of Nursing Oncology™ was developed to provide the latest information on key topics in oncology that can readily be applied to nursing clinical practice in a variety of settings. This enduring activity features faculty video commentary on key topics presented at the live meeting, including strategies to help optimize patient management and insights into the evolving treatment landscape for a variety of commonly encountered malignancies. This activity will also address such topics as landmark and recent key trials in oncology, and the clinical implications of their results.
Instructions for This Activity and Receiving Credit
This educational program is directed toward nurses interested in the management of patients with cancer. Other healthcare professionals interested in the management of patients with cancer are also invited to attend.
At the conclusion of this activity, you should be better prepared to:
Grace Cherry, RN, MSN, NP
Oncology Nurse Practitioner
UCLA Melanoma Program
Los Angeles, CA
Disclosure: Consultant: Array; Speaker: Merck, Novartis
Beth Eaby-Sandy, MSN, CRNP, OCN
Thoracic Oncology Nurse Practitioner
Abramson Cancer Center
Hospital of the University of Pennsylvania
Disclosure: Consultant: AbbVie; Speaker: Takeda, AstraZeneca, Helsinn, Merck
Laura S. Wood, RN, MSN, OCN
Renal Cancer Research Coordinator
Cleveland Clinic Taussig Cancer Center
Disclosure: Speaker: Bristol-Myers Squibb, Merck, Pfizer
The staff of Physicians' Education Resource®, LLC, (PER®) have no relevant financial relationships with commercial interests to disclose.
As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.
Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.
Dec 31, 2018
Medical Crossfire®: Defining New Roles for the Application of PARP Inhibition Strategies in Multiple Tumor Types
Dec 31, 2018
Dec 31, 2018